SPOTLIGHT -
Dr. Emmanuel S. Antonarakis on the Future of the AR-V7 Biomarker in Prostate Cancer
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, on the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker.
AR-V7 as a Biomarker in CRPC
Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
